comparemela.com

Latest Breaking News On - Ulrich osswald - Page 1 : comparemela.com

Lonza Launches New Cell Line and MilliporeSigma Introduces Digital Reference Materials Platform

Lonza Launches New Cell Line and MilliporeSigma Introduces Digital Reference Materials Platform
genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.

Jean charles wirthUlrich osswaldMerck kgaaMerck kgaAtul mohindra

Lonza Group AG: Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering

Lonza Group AG / Key word(s): Acquisition/Mergers & Acquisitions Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering 01.06.2023 / 07:00 CET/CEST Lonza to acquire

Noord hollandMicrotubule syntansineMicrotubule synstatinAnthony deboerSynaffixbv synaffixUlrich osswaldEleanor cooperInnovent biologicsWilliam blairLyle wheelerChong kun dang pharmaPlatform technologySingapore exchange securities trading limitedSwiss exchangeBusiness developmentLonza group ltd

Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering

DJ Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering Lonza Group AG / Key word(s): Acquisition/Mergers & Acquisitions Lonza to Acquire Synaffix and Strengthen Antibody-Drug

Noord hollandMicrotubule syntansineMicrotubule synstatinWilliam blairChong kun dang pharmaInnovent biologicsUlrich osswaldEleanor cooperSynaffixbv synaffixBusiness developmentSwiss exchangeLonza group ltdPlatform technology synaffixSingapore exchange securities trading limitedDisclaimer lonza group ltdCapsules health ingredients

Lonza to acquire Synaffix to strengthen ADC development

Synaffix’s technology platform is intended to enhance and extend Lonza’s integrated ADC services - News - PharmaTimes

Ulrich osswaldDrug development

Lonza strengthens ADC offering with Synaffix acquisition

Lonza has acquired Synaffix B.V., a biotech company focused on commercializing its clinical-stage technology platform for the development of antibody drug conjugates (ADCs).

Ulrich osswaldMarkets amp regulationsAntibody drug conjugates

vimarsana © 2020. All Rights Reserved.